All‐cause mortality at last · people with liver metastases
It is very uncertain whether percutaneous ethanol injection changes mortality at last compared with no intervention, other ablation methods, or systemic treatment (very low certainty).
1 finding from 1 review
Time to mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases
It is very uncertain whether percutaneous ethanol injection changes failure to clear liver metastases or recurrence of liver metastases compared with no intervention, other ablation methods, or systemic treatment (very low certainty).
1 finding from 1 review
Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response measures · people with liver metastases
1 finding from 1 review
Serious adverse events and complications · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Local progression · 1088 patients with early HCC
1 finding from 1 review
Rate of complications · 1088 patients with early HCC
1 finding from 1 review
Length of hospital stay · 1088 patients with early HCC
1 finding from 1 review
Overall survival · 1088 patients with early HCC
1 finding from 1 review
2‐year survival · 1088 patients with early HCC
1 finding from 1 review
Event‐free survival · 1088 patients with early HCC
1 finding from 1 review
Overall survival · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes proportion of people with disease progression compared with percutaneous ethanol injection (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes adverse events considered non‐serious (number of participants) compared with percutaneous ethanol injection (very low certainty).
1 finding from 1 review
Intervention not reported
PEI versus PAI · hospitalised people with early HCC treated with PEI, PAI, or surgery.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival · hospitalised people with early HCC treated with PEI, PAI, or surgery.
1 finding from 1 review
no estimate extracted
185 participants
Low